Eledon Pharmaceuticals' Tegoprubart Anchors Immunosuppression Regimen for Massachusetts General Hospital Pig Kidney Recipient Who Reached One Year of Organ Survival, the Longest Reported in a Living Human

November 24, 2026

Tegoprubart has been part of the immunosuppression regimen in every eGenesis pig kidney transplant performed in living humans and is included in the protocol for the planned RESTORE Phase 1/2/3 study expected to begin in the first quarter of 2027

IRVINE, Calif., Nov. 24, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today highlighted that a patient with end stage kidney disease who received a genetically engineered pig kidney at Massachusetts General Hospital (MGH) on November 22, 2025, has reached one year of kidney function, marking the longest reported duration for a pig kidney in a living human. Tegoprubart, the company's investigational anti-CD40L antibody, was used as a cornerstone of the patient's immunosuppression regimen to prevent transplant rejection.

The genetically engineered pig kidney, EGEN-2784, was developed by eGenesis, Inc. ("eGenesis"). The previous reported record of 271 days was attained by another MGH patient, Tim Andrews, who received an eGenesis developed kidney as a bridge to receiving a human donor kidney. Tegoprubart has been part of the immunosuppression regimen in every pig-to-human living kidney xenotransplant with an eGenesis organ performed at MGH, beginning with the world's first transplant of a genetically engineered pig kidney into a living person in March 2024.

Tegoprubart is also included in the immunosuppression regimen specified in the protocol for RESTORE, eGenesis's FDA-cleared Phase 1/2/3 study of EGEN-2784. The study is designed to enroll 33 patients requiring kidney transplantation. eGenesis has said it expects to begin the study in the first quarter of 2027.

"Reaching one year with a functioning pig kidney in a living human is a remarkable milestone for the xenotransplantation field and underscores the importance of effective immune modulation in achieving long-term organ survival, " said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. "We are proud that our investigational therapy, tegoprubart, was part of the immunosuppression regimen and believe that CD40L blockade with tegoprubart has the potential to transform the standard of care in transplantation across every organ and cell type, whether from human donors or engineered."

Beyond xenotransplantation, tegoprubart is being studied in kidney transplantation, islet cell transplantation, liver transplantation, and tolerance induction. Most recently in October, new patient-reported outcomes data from the Phase 2 BESTOW clinical program demonstrated sustained improvements in quality of life and symptom burden in kidney transplant recipients treated with tegoprubart compared with tacrolimus, today's standard of care immunosuppression therapy. The results were presented at the American Society of Nephrology (ASN) Kidney Week 2026 Annual Meeting. Eledon plans to initiate the global Phase 3 Legacy trial of tegoprubart in kidney transplantation in the fourth quarter of 2026. Tegoprubart has previously been used in pig-to-human heart xenotransplantation.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company's website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; X

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the Company's future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "predicts," "projects," "targets," "looks forward," "could," "may," and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Specifically, our ability to achieve our anticipated future development and corporate milestones depends on our ability to obtain additional financing on acceptable terms. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to maintain proper and effective internal control over financial reporting and other risks disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 19, 2026. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements contained herein, are discussed in our Annual Report on Form 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking

statements contained in this press release speak only as of the date hereof and not of any future date, and the Company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
CG Life
(212) 253-8881
jurban@cglife.com

